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Abstract 41 
Background 42 
External validation of prediction models is important to assess generalisability to 43 
other populations than the one used for model development. The Predicting Asthma 44 
Risk in Children (PARC) tool, developed in the Leicestershire Respiratory Cohort 45 
(LRC), uses information on preschool respiratory symptoms to predict asthma at 46 
school age.  47 
Objective 48 
We performed an external validation of PARC using the Avon Longitudinal Study of 49 
Parents and Children (ALSPAC).  50 
Methods 51 
We defined inclusion criteria, prediction score items at baseline and asthma at 52 
follow-up in ALSPAC to match those used in LRC using information from parent-53 
reported questionnaires. We assessed performance of PARC by calculating 54 
sensitivity, specificity, predictive values, likelihood ratios, area under the curve 55 
(AUC), Brier score and Nagelkerke’s R-squared. Sensitivity analyses varied inclusion 56 
criteria, scoring items and outcomes. 57 
Results 58 
The validation population included 2690 children with preschool respiratory 59 
symptoms of which 373 (14%) had asthma at school age. Discriminative performance 60 
of PARC was similar in ALSPAC (AUC=0.77, Brier score 0.13) as in LRC (0.78, 0.22). 61 
The score cut-off of 4 showed the highest sum of sensitivity (69%) and specificity 62 
(76%) and positive and negative likelihood ratios of 2.87 and 0.41, respectively. 63 
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Changes to inclusion criteria, scoring items or outcome definitions barely altered the 64 
prediction performance. 65 
Conclusion 66 
Performing equally well in the validation cohort as in the development cohort, PARC 67 
is a valid tool for predicting asthma in population based cohorts. Its use in clinical 68 
practice is ready to be tested. 69 
 70 
1. What is already known about this topic?  71 
Several childhood asthma prediction models have been developed, but few have 72 
been externally validated. 73 
2. What does this article add to our knowledge?  74 
We found that the simple 10-item PARC asthma prediction tool performed equally 75 
well in a different study population and identified symptomatic preschool children 76 
who were likely to have asthma  at school-age.  77 
3. How does this study impact current management guidelines? 78 
PARC is a simple non-invasive tool for predicting school-age asthma in symptomatic 79 
preschool children. It can be used to recruit high-risk children for clinical trials and its 80 
use in clinical practice is ready to be tested. 81 
 82 
 83 
Keywords:  84 
Asthma; Wheeze; Prediction; External Validation; PARC; Leicestershire Respiratory 85 
Cohorts; ALSPAC 86 
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Introduction 96 
Up to 40% of all preschool children have recurrent respiratory symptoms such as 97 
wheeze or cough but only about a quarter of these will have asthma at school age 98 
(1-4). Prediction models can be useful to identify those whose problems will persist. 99 
The ability to make an accurate prognosis can guide clinical decision-making and 100 
facilitate the selection of children for high-risk cohorts or clinical trials (5). Prediction 101 
models must be carefully developed using sound methodology for selecting 102 
prediction variables and examine discriminative performance and assess calibration  103 
(6). Prediction models may however not perform as well when applied to 104 
populations other than the ones they were developed in. External validation (in 105 
another population) is therefore necessary to assess the generalisability (7, 8). 106 
 107 
Several models to predict later asthma in preschool children have been developed 108 
(9). Most use a combination of demographic information, symptoms and results of 109 
clinical tests (e.g. lung function or allergic sensitisation) (10-17). These models are 110 
useful for specialised clinical settings, where spirometry, body plethysmography and 111 
skin prick test can be done. Two tools use only demographic information and 112 
symptoms; information easily obtained from parental questionnaires or when taking 113 
patient history in a medical consultation, which makes these models more widely 114 
applicable (18, 19). One of these was developed by our group, the Predicting Asthma 115 
Risk in Children (PARC) tool. It was developed using data from the Leicestershire 116 
Respiratory Cohorts, a population-based cohort study from the United Kingdom (19). 117 
Four childhood asthma prediction models have been externally validated. The 118 
Asthma Predictive Index (API) (10) was validated in five external cohorts (11, 15, 20-119 
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22), the PIAMA risk score (18) was validated in two external cohorts (21, 23), the Isle 120 
of Wight was validated in one external cohort (24) and the PARC tool was validated 121 
in a German asthma cohort, where it showed good predictive properties (25). 122 
However, this was a cohort, in which mothers with a history of allergy were 123 
overrepresented.  124 
We aimed to validate PARC in a larger population based cohort in the Avon 125 
Longitudinal Study of Parents and Children (ALSPAC). We calculated measures of 126 
prediction performance and assessed the robustness of prediction performance to 127 
changes in the inclusion criteria, the prediction score items and the outcome.  128 
 129 
Methods 130 
We used the Transparent Reporting of a multivariable prediction model for 131 
Individual Prognosis Or Diagnosis (TRIPOD) guidelines to report this external 132 
validation study (26).  133 
Predicting Asthma Risk in Children (PARC) 134 
The PARC tool was developed as a simple, low-cost, and non-invasive method to 135 
predict the risk of later asthma in symptomatic preschool children (19). It uses 136 
parental information about respiratory symptoms in 1-3 year old children to predict 137 
parental reported asthma five years later. The 10 scoring factors are: sex, age, 138 
wheeze without colds, number of wheezing episodes, shortness of breath due to 139 
wheeze, wheeze interfering with daily activities, exercise or allergy as triggers of 140 
wheeze, a history of eczema, and parental history of asthma and bronchitis. The 141 
published model was developed using the least absolute shrinkage and selection 142 
operator (LASSO) penalised logistic regression to avoid overfitting and simplified into 143 
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an easy-to-use tool. We validated the tool internally by using the leave-one-out 144 
cross-validation method (19). The sample size was judged to be sufficient based on 145 
the one-variable-per-ten-events rule, which suggests that at least ten outcome 146 
events per potential predictor considered are needed, to develop a model that can 147 
generalize to other samples (8). We considered 38 potential binary predictors (from 148 
24 original variables) and the sample included 345 children with asthma. 149 
Development cohort, LCR 150 
As described previously (19), the PARC tool was developed using data from the 151 
Leicestershire Respiratory Cohort study (LRC). The LRC is a longitudinal population-152 
based study from Leicestershire, United Kingdom (27). For the development of PARC, 153 
we used data from 6808 children born in 1993-1997. Data for inclusion criteria, 154 
prediction score items and outcomes came from questionnaires on respiratory 155 
symptoms and general health that parents completed at baseline in 1998 and 1999 156 
when the children were aged 1-3 and at follow-up in 2003 when the children were 157 
aged 6-8 years. The Leicestershire Health Authority Research Ethics Committee 158 
approved the study. 159 
External validation cohort, ALSPAC 160 
In the present study, we used data from the ALSPAC cohort to validate the PARC 161 
tool. ALSPAC is a longitudinal birth cohort that recruited 14541 pregnant women 162 
from Avon, United Kingdom, with expected delivery between April 1991 and 163 
December 1992, resulting in 14062 live born children. The study has been described 164 
in detail previously (28). Mothers and their partners filled in questionnaires about 165 
their own and their child’s health approximately yearly from when the children were 166 
6 months old. We used baseline information from the questionnaires filled in when 167 
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the child was 1.5, 2.5 and 3.5 years to define inclusion criteria and calculate the 168 
prediction score and information from questionnaires completed at age 6 and 7 169 
years to assess asthma at school age. The ALSPAC study was approved by the 170 
ALSPAC Ethics and Law Committee and from Local Research Ethics Committees. 171 
Inclusion criteria 172 
We defined inclusion criteria for ALSPAC that resembled the inclusion criteria used in 173 
the LRC (table 1). We included children aged 1.5 to 3.5 years from ALSPAC who had 174 
had wheeze or cough during the past 12 months (Has your child experienced 175 
wheeze/cough during the past 12 months?) and saw a doctor for one of these 176 
problems (answer category: yes and saw a doctor) plus had valid information on 177 
current wheeze and use of asthma medication at age 7.5 years.  178 
Calculation of prediction scores 179 
Items used for the prediction score are presented in Table 3 for LRC and ALSPAC. In 180 
ALSPAC, the same questionnaires were sent to the parents at 1.5, 2.5 and 3.5 years 181 
of age. In order to achieve a comparable age distribution in ALSPAC as in the LRC, the 182 
baseline information was taken from the questionnaire filled at age 1.5 year for 28% 183 
of the study population, at age 2.5 for 57% and at age 3.5 for 15%. The age at which 184 
baseline information was taken for a given child, was obtained by random sampling 185 
ensuring this overall age distribution. Information on parental history of wheeze, 186 
asthma and bronchitis came from a questionnaire sent to the mother at 12 weeks 187 
gestation and from a questionnaire sent to the partner when the child was 33 188 
months old. The prediction score was calculated as the sum of score-points from 189 
each item (table 3). We also assigned predicted probabilities for later asthma to 190 
these scores as suggested in our report on the development of PARC (19). 191 
10 
 
 
 
Definition of outcome 192 
In the original cohort, we had defined the outcome ‘asthma’ as ‘current wheeze plus 193 
use of asthma inhalers in the past 12 months’. To match this outcome definition in 194 
ALSPAC, we defined ‘asthma’ as ‘yes’ to the parent reported current wheeze (‘Has 195 
he/she had wheeze in the past 12 months’) plus current use of asthma medication 196 
(‘Please indicate which of the following have been given to your child in the last 12 197 
months? Asthma medication’).  198 
 199 
Assessing predictive performance 200 
We assessed how well the calculated PARC prediction scores predicted later asthma 201 
in children from the ASLPAC cohort using measures of discrimination (the ability of 202 
the score to discriminate between children who had asthma at school age and those 203 
who had not) and calibration (the ability of the tool to predict the probability of later 204 
asthma) (8). To assess discrimination, we calculated sensitivity, specificity, positive 205 
predictive value, negative predictive value, and positive and negative likelihood 206 
ratios for each possible cut-off value of the score.  We also plotted receiver operator 207 
curves (ROC) and calculated area under the curve (AUC). To assess calibration, we 208 
assigned the probabilities of later asthma to each score value as proposed in the 209 
original article by Pescatore et al. (19). Based on these predicted probabilities, we 210 
first calculated maximum rescaled Brier score and Nagelkerke’s R2 as overall 211 
performance measures (8). These measures can be interpreted as “goodness-of-fit 212 
measures” showing how well the predicted probability approximates the outcome 213 
on a scale between 0 and 1, with 1 indicating perfect prediction and 0 representing a 214 
non-informative model, in which a constant probability equalling the prevalence of 215 
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the outcome is predicted for each child. Details on how to compute these measures 216 
are provided in the supplementary text E1. We examined calibration of the PARC 217 
tool graphically by plotting the predicted probability for each value of the score 218 
against the observed frequency of asthma among ALSPAC children with that score 219 
value, using the function calibrate.plot and val.prob.ci.2 from the ‘gbm’ package in R 220 
(29). We excluded children if they had missing information in any of the scoring 221 
variables (8%) apart from the item ‘partner’s history of wheeze, asthma and 222 
bronchitis’, for which 25% had missing information. For these children, we set 223 
missing information about the partner to ‘no history’.  224 
In a separate analysis, we recalibrated the PARC scores in the ALSPAC cohort, by 225 
fitting a logistic regression of the outcome on the calculated scores (as a linear term) 226 
used in the main analysis above. For each child, we then calculated recalibrated 227 
scores as the value of the linear predictor from this regression. We then compared 228 
calibration performance of these scores with that of the original scores.  229 
We used STATA 14 for data preparation and descriptive analysis and R version 2.1 to 230 
study model performance and model fit. 231 
 232 
Sensitivity analyses 233 
To test the robustness of PARC, we performed sensitivity analyses in ALSPAC and LRC 234 
datasets using alternative definitions of the included population, prediction score 235 
items and outcome definitions (supplementary table E2). Firstly, we restricted age 236 
at baseline by including children aged 1.5 only, 2.5 only and 3.5 years only (only 237 
ALSPAC). Secondly, we altered the inclusion criteria to 1) any wheeze in the past 12 238 
months, and 2) any cough in the past 12 months (only in ALSPAC). Thirdly, we 239 
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changed items in the prediction score by: 1) excluding ‘wheeze triggered by exercise 240 
or allergy’, as triggers of wheeze were measured differently in ALSPAC (open 241 
question) compared with LRC (specific response categories), and 2) exchanging 242 
‘wheeze without colds’ with ‘current wheeze’ (only in LRC), 3) setting missing 243 
information in the prediction score items to the lowest value instead of excluding 244 
children with missing values in the analysis. Fourthly, we used an alternative 245 
outcome definitions: severe asthma (ALSPAC: current wheeze and use of asthma 246 
medication on at least 3 episodes, LRC: wheeze on at least 4 episodes and use of 247 
asthma inhalers).  248 
Sample size 249 
There are no guidelines for the adequate sample size needed for external validations 250 
of prediction model but according to a simulation study by Collins et al. (30) ideally 251 
200 events are required. We had more than 300 events (asthma at age 7.5 years) in 252 
any of our analyses. 253 
 254 
Results 255 
Of the 14,541 children originally recruited in ALSPAC, 7200 children responded to 256 
the questionnaires at 1, 2, 3 and 7 years. Of these, 2921 fulfilled the inclusion criteria 257 
(saw a doctor for wheeze or cough in the past 12 months) and 2690 were included in 258 
our main analysis (231 were excluded due to missing information in one or more 259 
prediction score items). Not all questions used to specify inclusion criteria in the LRC 260 
were available in ALSPAC resulting in less restrictive inclusion criteria (table 1). Table 261 
2 shows similarities and differences between the two studies including location in 262 
the UK and the gender and age distribution. The two cohorts differed considerably in 263 
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ethnicity composition (98% whites in ALSPAC, 81% whites and 19% south Asians in 264 
LRC). 265 
 266 
Distribution of PARC score  267 
For most items of PARC we were able to use similar questions in ALSPAC as in the 268 
LRC (table 3). There were some differences for ‘wheeze without colds’, questions on 269 
triggers for wheeze and parental history of wheeze and bronchitis. Assigning scores 270 
to ALSPAC children resulted in a more left skewed distribution of the PARC score in 271 
ALSPAC compared with the LRC (Figure 1). The maximum and median values were 272 
lower in the ALSPAC cohort (max = 13, median = 2, Interquartile range: 2-4) 273 
compared with the LRC cohort (max = 14, median = 4, Interquartile range: 2-6). 274 
 275 
Frequency of asthma at follow-up 276 
In ALSPAC, 373 (14%) of the included children had the primary outcome at age 7.5 277 
years compared with 345 (28%) in LRC (table 2).  278 
 279 
Performance of PARC main analysis 280 
The discriminative ability of PARC was similar in ALSPAC and LRC (figure 2). ROC 281 
curves from ALSPAC and LRC were almost identical, AUC of 0.77 in ALSPAC and 0.78 282 
in LRC. In ALSPAC, the score cut-off maximizing the sum of sensitivity (69%) and 283 
specificity (76%) was 4, in LRC the best cut-off was 5 (sensitivity 72%, specificity 284 
71%). The validation analysis showed positive and negative predictive value of 0.32 285 
and 0.94 and positive and negative likelihood ratios of 2.87 and 0.41, all at score cut-286 
off 4 (discriminative values for all cut-off points in figure 2). Overall performance in 287 
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ALSPAC was comparable to that in LRC. The max-scaled Brier score was 0.13 in 288 
ALSPAC and 0.22 in LRC, the Nagelkerke’s R-squared was 0.23 in ALSPAC and 0.28 in 289 
LRC. The calibration assessment showed that PARC scores from the ALSPAC 290 
population were associated with a lower frequency of later asthma than predicted 291 
from the LRC (figure 3 and figure 4). After recalibrating the predicted probabilities in 292 
ALSPAC (figure 4B), our calibration plot showed good calibration of PARC in ALSPAC 293 
(Brier score = 0.17 for recalibrated main model). 294 
 295 
Sensitivity analyses 296 
Changes in inclusion criteria, prediction score items and definition of outcome 297 
resulted only in minor changes for most performance measures (table 4). In 298 
sensitivity analyses, PARC performed better in children aged 3.5 years (AUC = 0.78, 299 
R2 = 0.26), compared with 1.5 year-olds (AUC = 0.71, R2 = 0.13). Prediction was 300 
slightly worse in a population including only children who wheezed (AUC=0.73, R2 = 301 
0.18) compared with those who also saw a doctor or only children who coughed 302 
with or without seeing a doctor (AUC = 0.76, R2 = 0.20). The exclusion of trigger 303 
variables in ALSPAC barely altered the performance. PARC performed better when 304 
the main outcome was severe asthma (AUC = 0.78, R2 = 0.23). Sensitivity analysis 305 
where results excluding missing information were compared to results where 306 
missing information was set to zero showed no difference in the performance of 307 
PARC (data not shown). 308 
 309 
Discussion 310 
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We found that PARC predicted asthma at school age equally well in the validation 311 
cohort, ALSPAC (AUC 0.77), compared with the development cohort, LRC (AUC 0.78). 312 
Using a cut-off score value of 4, PARC predicted asthma with a sensitivity of 69% and 313 
specificity of 76%, which was similar to what was found in LRC for a cut-off score of 5 314 
(sensitivity = 72% and specificity = 71%). The calibration assessment showed that the 315 
observed frequency of asthma was generally lower in ALSPAC than predicted by the 316 
PARC score, but when we recalibrated the predicted probabilities to the ALSPAC 317 
population, agreement between predicted and observed asthma frequency was 318 
good. 319 
 320 
Limitations and strengths 321 
The information used to define the included population was not the same in ALSPAC 322 
as in LRC. Specifically, the ALSPAC cohort had insufficient information on night cough 323 
and cough without colds, so we replaced this information with a general question 324 
about cough. These relaxed inclusion criteria has led to inclusion of less severely 325 
affected children than the LRC population, which in turn explains the lower 326 
prevalence of asthma at school age (14% in ALSPAC compared with 28% in LRC). This 327 
did not affect the discriminative ability of PARC, but it affected calibration and the 328 
overall performance measures such as the Brier score. Furthermore, we lacked 329 
perfectly matched information on items needed to compute the PARC score. Key 330 
information for the score such as wheeze without colds and triggers of wheeze were 331 
not available in the same detail. However, our sensitivity analysis in ALSPAC 332 
suggested that exclusion of triggers of wheeze did not affect the performance much 333 
(AUC 0.77, same as main analysis). 334 
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 335 
A strength of our study was that we had full access to all data from the development 336 
and the validation cohort, which made it possible to compare the populations and 337 
assess discriminative performance and calibration of PARC directly. Secondly, the 338 
cohort used for the external validation was large and had collected questionnaire 339 
information yearly between birth and the age of 8 years. This enabled us to match 340 
and vary the age at which baseline and outcome information were collected. Thirdly, 341 
less than 5% of the information in the single variables used for scoring (apart from 342 
partner’s history of asthma and wheeze) was missing and we therefore excluded 343 
only a small number of the children satisfying the inclusion criteria (8%). Sensitivity 344 
analysis, in which missing information was set to zero, did not change our main 345 
results. Fourthly, for the primary outcome, we had perfectly maching on current 346 
wheeze and use of asthma medication at the age of 7.5 years, and we could 347 
therefore rule out that differences in performance of the PARC tool in ALSPAC and 348 
LRC cohorts were caused by different outcome definitions.  349 
 350 
Comparison with other studies 351 
One other study has investigated the external validity of PARC and found similar 352 
performance compared with the original cohort (25). The study used information 353 
from the German Multicentre Allergy Study (MAS-90) birth cohort with an 354 
overrepresentation of children from allergic parents. The authors included 140 355 
children in their validation population. The authors found that PARC predicted 356 
asthma with AUC= 0.83 and a sensitivity of 0.82, a specificity of 0.69 at a score of 5. 357 
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The calibration assessment showed good agreement between predicted 358 
probabilities of asthma and observed frequency.  359 
Of the other models developed to predict asthma in children, three have been 360 
externally validated (supplementary table E3). The Asthma Predictive Index 361 
developed using the Tucson Children’s Respiratory Study in 2000 (10) was externally 362 
validated in five separate studies (11, 15, 20-22), showing generally higher 363 
sensitivity, but lower specificity than in the development cohort, which could partly 364 
be explained by differences in inclusion criteria. Caudri et al. developed an asthma 365 
prediction model using the Prevalence and Incidence of Asthma and Mite Allergy 366 
birth cohort (PIAMA) (18), which was externally validated in a Columbian clinical 367 
cohort of children with wheeze (21) and in the Dutch population-based Generation R 368 
study (23) and showed similar performance compared with the development cohort. 369 
The calibration assessment showed that the PIAMA risk score systematically 370 
overestimated asthma risk at age 7 years. Kurukulaaratchy et al. developed a 371 
prediction model in the Isle of Wight birth cohort (13), which was applied in the 372 
British Multicentre Allergy Study (MAS) birth cohort, where calibration showed 373 
different predictive properties compared with the development cohort. The 374 
evidence from these external validation studies and the present study suggests that 375 
these prediction models are generally robust in different populations and 376 
discriminate asthma from no asthma well in different settings, but calibration must 377 
be assessed for the models to accurately predict asthma risk. Among the existing 378 
prediction models that have been externally validated, PARC and the PIAMA risk 379 
score are the models most easily applied in practice as they require no specific 380 
physiological measurements or blood investigations as does for example the API 381 
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(supplementary table E3). Additionally, PARC predicts as well or better than other 382 
existing asthma prediction tools when comparing the combined sensitivity and 383 
specificity using the Youden Index (31) (sensitivity + specificity – 1, calculated based 384 
on the maximal sum of sensitivity and specificity), which ranges from 0 to 1 with 1 385 
indicating perfect prediction. Reported values of the Youden index are 0.43 for PARC 386 
compared with 0.32 for the API, 0.36 for the PIAMA risk score and 0.38 for the Isle of 387 
Wight score (19). PARC has a similar positive likelihood ratio (true positives/false 388 
positives) (+LR = 2.5) compared with the PIAMA risk score (+LR = 2.5) but lower 389 
than the API (+LR = 7.8) and the Isle of Wight (+LR = 3.4) (supplementary table 390 
E3). These differences could be due to different inclusion criteria used for the 391 
study populations in which the prediction scores were developed. The API was 392 
developed in a general population sample including mostly healty children. Such 393 
a population has a a low baseline risk of asthma at follow-up whereas the 394 
populations used for PARC and the PIAMA score included only children visiting 395 
doctors for wheeze or chronic cough who thus had a higher baseline risk of 396 
asthma at follow-up. In a population with low baseline risk, it may be easier to 397 
correctly identify those that will not develop asthma, which increases specificity 398 
and, assuming the same sensitivity, increases the positive likelihood ratio. Also, 399 
the positive likelihood ratio can be interpreted as the ratio of posterior odds 400 
(after a model predicts that a child will have asthma based on baseline 401 
information) of having later asthma to the prior odds (ignoring baseline 402 
information). A higher positive likelihood ratio is needed to achieve the same 403 
posterior likelihood of asthma if the baseline risk is low compared to when it is 404 
high. 405 
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 406 
Interpretation 407 
PARC predicted asthma better in children who were older at the baseline survey. A 408 
reason for this could be that the aetiology of wheeze in children age less than 2 409 
years is more heterogeneous and only a small proportion will eventually have 410 
asthma. In a study using data from ALSPAC, Henderson et al. (32) investigated 411 
wheezing phenotypes over time and found a majority of children with the 412 
phenotype transient early wheeze begin wheezing in the first two years of life. In our 413 
data we saw that more children fulfilled our inclusion criteria early in life (3583 1.5-414 
year-olds compared to 2238 3.5-year-olds), but the proportion of children that had 415 
asthma at school age was lower among children aged 1.5 years initially (12%) than in 416 
children aged 3.5 years at baseline (19%). This may explain the poorer prediction, 417 
particularly poorer calibration, among 1.5 year-olds. 418 
The different phenotypes of wheeze might also explain why the predictive 419 
performance of PARC was better for severe asthma. Several studies have identified a 420 
phenotype characterised by persistence of symptoms from an early age (3, 32, 33). 421 
Children with this phenotype tend to have more wheezing episodes, more often use 422 
bronchodilators, and cough without colds compared with wheeze phenotypes with 423 
late onset transient or viral wheeze. Because severity tends to track (34), PARC 424 
identifies those with more severe disease at school age because these children often 425 
had already severe symptoms early in life. As disease burden is greater in children 426 
with severe asthma, they are the main target group for interventions. 427 
The discriminative ability of PARC appears robust to changes in item and population 428 
definitions. Although different questions were used in the two cohorts, they 429 
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probably measure similar concepts. This makes PARC useful also in settings with 430 
misclassification of information. Outcome prevalence appears to be the more critical 431 
factors affecting predictive performance. Therefore, if PARC is to be used in a 432 
population with outcome-prevalence very different from that in LRC, we recommend 433 
simple recalibration of the PARC, which allows obtaining risk-probabilities that are 434 
closer to the observed frequencies. Practically, one approach for calibration could be 435 
to examine the prevalence of school-age asthma in the population in question and 436 
compare it to LRC or ALSPAC. If the observed frequencies are similar to those in LRC 437 
or ALSPAC, the predicted probabilities calculated in the original study or this 438 
validation study can be used. If the prevalence is much higher or much lower, it 439 
might be necessary to collect (possibly retrospectively from medical records) 440 
information from a subsample of children to fill in the PARC tool and thereby 441 
calculate new predicted probabilities.  442 
The ALSPAC cohort did not offer the possibility to validate the PARC tool in different 443 
ethnic groups as the ALSPAC included 98% whites. The PARC tool would need to be 444 
externally validated in a sample with a larger ethnic diversity to determine the 445 
generalizability of PARC in different ethnic settings. 446 
The sample size in the original development of the PARC prediction model was 447 
estimated to be sufficient according to the one-variable-per-ten-events rule with 24 448 
potential predictor variables (represented by 38 binary variables) and 345 events 449 
(35). However, the appropriateness of this rule has been questioned (36). It is 450 
possible that our original study did not have sufficient statistical power to identify 451 
some important predictors among the 38 predictors considered, although 10 of 452 
these were retained in the final model and are used in the PARC tool. That the PARC 453 
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tool includes irrelevant predictors as a result of overfitting is less likely as we used 454 
penalised logistic regression to build the tool. Furthermore, almost all predictors 455 
included in PARC are either recognised risk factors (male sex, parental history) or are 456 
indicators of atopy or symptom severity, which are both known to be associated 457 
with persistence. The only exception is older age (≥ 1 year), which is a plausible 458 
predictor, as wheeze or cough in infancy is more transient and usually associated 459 
with respiratory infections.  460 
 461 
Conclusion 462 
This validation study showed that PARC has the same ability to identify preschool 463 
children who are likely to develop asthma at 7.5 years in a population different from 464 
the development cohort. The discriminative ability of the tool appears to be robust 465 
to changes in inclusion criteria, scoring variables and outcome definitions suggesting 466 
that PARC is robust to misclassification of information. Our study suggests that the 467 
tool may need recalibration when applied to populations, in which the outcome 468 
prevalence differs greatly from the development cohort. PARC is a valid tool for 469 
predicting asthma in pre-school children and its use in clinical practice is ready to be 470 
tested.  471 
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Figure legends 503 
Figure 1: Distribution of the PARC scores* (relative frequency) in the external 504 
validation population (ALSPAC, n=2690, black) and original development population 505 
(LRC, n=1226, grey).  506 
 507 
Figure 2: Receiver operating characteristic (ROC) from validation population ALSPAC 508 
(solid line) and the original development population LRC (dashed line). Numbers (1-509 
13) indicate asthma prediction score values and their corresponding positions 510 
(indicated in red on the figure). The area under the curve (AUC) corresponds to the 511 
primary outcome in both cohorts. The table above the figure shows sensitivity 512 
(Sens), specificity (Spec), positive and negative predictive values (PPV, NPV) and 513 
likelihood ratios (LR+, LR-) for each score point in ALSPAC.  514 
 515 
Figure 3: Predicted probability of developing asthma at follow-up in LRC (dashed 516 
grey line) and probabilities predicted by the recalibrated model in ALSPAC (black 517 
line). 518 
 519 
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Figure 4: Calibration assessment of predicted probabilities vs. observed asthma 520 
frequencies in seven equally sized groups. Figure A displays the calibration 521 
assessment for the predicted probabilities calculated in LRC. Figure B displays the 522 
probabilities predicted by the recalibrated model in ALSPAC. Shaded areas represent 523 
exact pointwise 95%-CI for asthma frequency. The diagonal red line represents 524 
perfect calibration.   525 
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Table 1: Inclusion criteria and outcome definitions in LRC and ALSPAC 
LRC: items for inclusion criteria* (at 
age 1-3 years) 
Answer categories ALSPAC: items for 
inclusion criteria*  (at age 
0.5, 1.5, 2.5 years) 
Answer categories  Comparability 
Has your child had wheezing or 
whistling in the chest in the last 12 
months? 
Yes, no Has he had any of the 
following the last 12 
months, wheezing?  
Yes and saw a doctor 
Yes but did not see doctor 
No did not have 
Good 
     
Does your child usually have a cough 
without colds? 
Yes, no Has he had any of the 
following the last 12 
months, cough? 
Yes and saw a doctor 
Yes but did not see doctor 
No did not have 
Moderate 
     
In the last 12 months, has your child 
had a dry cough at night, apart from 
a cough associated with a cold or a 
chest infection? 
Yes, no No question - - 
     
How often did your child see a GP for 
coughing or wheezing during the last 
12 months? 
Never, once, 2-3 
times, 4-6 times, 7 
or more times 
Has he had any of the 
following the last 12 
months, wheezing? 
Yes and saw a doctor 
Yes but did not see doctor 
No did not have 
Good 
     
In the last 12 months, has wheezing 
or asthma resulted in your child: (4 
categories: referred/admitted to 
hospital, attending/calling ER or GP) 
Yes, no No question - - 
LRC: items for outcome definition@ 
(at 8 years) 
Answer categories ALSPAC: items for 
outcome definition@ (at 
7.5 years) 
Answer categories Comparability 
Has your child had wheezing or 
whistling in the chest in the last 12 
months? 
Yes, no Has he had any of the 
following in the past 12 
months, wheezing? 
Yes and saw a doctor 
Yes but did not see doctor 
No did not have 
Very good 
     
Did your child take any of the 
following during the last 12 months? 
(4 categories: inhalers by 
content/type) 
Yes, no, don’t know Please indicate which of 
the following have been 
given to your child the last 
12 months. - Asthma 
medication? 
Never 
Yes for 1-2 episodes only 
Yes for 3 or more episodes 
Very good 
*Inclusion criteria LRC: Wheeze or cough (cough without colds or cough at night) with 1 or more visits to the doctor for wheeze or cough 
during the past 12 months). Inclusion criteria ALSPAC: Wheeze or cough during the past 12 months and saw a doctor for one of these 
problems (answer category: yes and saw a doctor). @Outcome definition LRC: ‘Yes’ to wheeze and use of asthma medication past 12 
months. Outcome definition ALSPAC: Outcome definition ALSPAC: ‘Yes’ to wheeze and use of asthma medication past 12 months. 
 
 
Table 1
Table 2: Comparison of study characteristics and demographic factors in development cohort (LRC) 
and external validation cohort (ALSPAC) 
 Development cohort (LRC) 
N=1226 
Validation cohort (ALSPAC) 
N=2690 
Location Leicestershire (United Kingdom) Bristol (United Kingdom) 
   
Study design Prospective cohort (from birth) Prospective cohort (from pregnancy) 
   
Recruitment General population random sample General population random sample 
   
Year of birth 1995-1997 1991-1992 
   
Sex   
male 678 (55) 1433 (54) 
   
Ethnicity   
White 797 (69) 2580 (98) 
South Asian 305 (26) - 
Other 57 (5) 52 (2) 
   
Baseline Assessment   
     Age®   
     1 year  336 (27) 763 (28) 
     2 years  702 (57) 1516 (56) 
     3 years  188 (15) 411 (15) 
     Wheeze* prevalence 766 (62) 791 (29) 
     Cough* prevalence 1085 (89) 2654 (99) 
   
Follow-up Assessment   
      Age   
      6 years 336 (27)  
      7 years  702 (57) 2690 (100) 
      8 years 188 (15)  
      Wheeze* prevalence 427 (35) 451 (17) 
      Cough* prevalence   
      Use of asthma medication* 345 (28) 586 (22) 
      Wheeze* + use of asthma medication* 345 (28) 373 (14) 
This table is displayed using n (%) unless otherwise stated. ®The age distribution at baseline in ALSPAC was matched to the baseline age 
distribution in LRC, * in the past 12 months. Prevalence of wheeze and cough is so high, because only children with lower respiratory 
symptoms were included. 
 
Table 2
Table 3: Questionnaire items used for scoring and their distribution in LRC and ALSPAC 
Item 
Nr. 
Question item in 
LRC 
Score value (%) Questionnaire item in 
ALSPAC  
Score value (%) Comparability 
1 What is the child’s 
sex 
Female = 0 (45) Sex Female = 0 (47) Perfect 
  Male = 1 (55)  Male = 1 (53)  
2 How old is the child? 1 years = 0 
2 years = 1 
3 years = 1 
(27) 
(57) 
(15) 
Age  1 years = 0 
2 years = 1 
3 years = 1 
(28) 
(57) 
(15) 
Perfect 
3 In the last 12 
months, has the 
child had wheezing 
or whistling in the 
chest even without 
having a cold or flu? 
No = 0 
Yes = 1 
(82) 
(18) 
Since she was 6/18/30* 
months old has she had any 
periods when there was 
wheezing with whistling on 
her chest when she breathed? 
No = 0 
Yes = 1 
(71) 
(29) 
Moderate. 
Question does 
not include 
‘without cold’  
4 How many attacks of 
wheeze has the child 
had during the last 
12 months? 
0-3 = 0 
>3 = 2 
(77) 
(23) 
Has your baby ever had 
wheezing with whistling on 
her chest when she breathed? 
b) How many separate times 
has this happened 
0-3 = 0 
>3 = 2 
(82) 
(18) 
Very good  
5 In the last 12 
months, how much 
did wheezing 
interfere with your 
child’s daily 
activities? 
Never=0 
A little = 1 
A lot = 2 
(64) 
(26) 
(10) 
Proxy: ‘how many days 
altogether would you say he 
had wheezed in the past 12 
months?’ 
0-3 days = 0 
4-19 days = 1 
20 or more days = 2 
(77) 
(16) 
(7) 
Poor. Different 
question.  
6 Do these wheezing 
attacks cause 
him/her to be short 
of breath? 
Never = 0 
Sometimes = 2 
Always = 3 
(65) 
(29) 
(6) 
Since she was 6/18/30* 
months old has she had any 
periods when there was 
wheezing with whistling on 
her chest when she breathed? 
d) Was he breathless 
(struggling for breath) during 
any of these times? 
No for all = 0 
Yes for some = 2 
Yes for all = 3 
(84) 
(15) 
(1) 
Very good 
7 In the last 12 
months, did exercise 
(playing, running) or 
laughing, crying or 
excitement cause 
wheezing or 
coughing in the 
child? 
No = 0 
Yes = 1 
(61) 
(39) 
has your baby ever had 
wheezing with whistling on 
her chest when she breathed? 
g) what do you think brings 
them on? (exercise, emotion) 
No = 0 
Yes = 1 
(99) 
(1) 
Moderate. 
Optional free 
text field – few 
answers 
8 In the last 12 
months, did contact 
with dust, grass, pets 
or other animals 
cause wheezing or 
coughing in the 
child? 
No = 0 
Yes = 1 
(93) 
(7) 
has your baby ever had 
wheezing with whistling on 
her chest when she breathed? 
g) what do you think brings 
them on? (allergy) 
No = 0 
Yes = 1 
(99) 
(1) 
Moderate. 
Optional free 
text field –  few 
answers 
9 Has the child ever 
had eczema? 
No = 0 
Yes = 1 
(57) 
(43) 
Has the baby had a rash in the 
joints and creases of her body 
(e.g. behind the knees, under 
the arms)? 
No = 0 
Yes = 1 
(71) 
(29) 
Good. Asking 
about rash 
instead of 
eczema 
10 Has the child’s 
parents ever 
suffered from 
wheezing, asthma or 
bronchitis? 
None = 0 
Mother = 1 
Father = 1 
Both = 1 
(52) 
(17) 
(22) 
(9) 
Have you ever had any of the 
following problems: asthma/ 
Wheezing past 2 years 
Have you had wheeze or 
bronchitis since the child was 
born (8 month after birth) 
None = 0 
Mother or father = 
1 
Both = 1 
(65) 
 
(31) 
(4) 
Moderate. 
Information 
asked from 
partner instead 
of father.  
*ages correspond to age 12 months prior to questionnaire mailing 
 
 
Table 3
Table 4: Predictive performance of PARC for main analysis and sensitivity analyses in ALSPAC and LRC (definitions of main and sensitivity analyses in table E1) 
 
 ALSPAC n Cases (%) Sens Spec PPV NPV LR+ LR- AUC R2 Brier score 
             
A1 Main analysis 2690 373 (14) 0.69 0.76 0.32 0.94 2.87 0.41 0.77 0.23 0.13 
A2 Altered inclusion criteria            
A2.1      Only children aged 1 year 3583 439 (12) 0.51 0.80 0.26 0.92 2.53 0.61 0.71 0.13 0.06 
A2.2      Only children aged 2 years 2817 410 (14) 0.69 0.72 0.29 0.93 2.42 0.44 0.76 0.21 0.07 
A2.3      Only children aged 3 years 2238 396 (19) 0.62 0.82 0.43 0.91 3.46 0.46 0.78 0.26 0.21 
A2.4      Wheeze past 12 months 1423 326 (23) 0.81 0.46 0.31 0.89 1.49 0.42 0.73 0.18 0.08 
A2.5      Cough past 12 months 6351 554 (9) 0.52 0.87 0.28 0.95 4.11 0.55 0.76 0.20 0.07 
A3 Altered scoring variables            
A3.1      Exclude trigger variables 2690 373 (14) 0.69 0.76 0.32 0.94 2.89 0.41 0.77 0.23 0.13 
A4 Altered outcome definition            
A4.1      Severity: Wheeze past 12 months and use    
     of asthma medication at 3 or more episodes 
2688 307 (11) 0.70 0.75 0.26 0.95 2.78 0.40 0.78 0.23 0.06 
 LRC            
             
L1 Main analysis 1226 345 (28) 0.79 0.57 0.42 0.87 1.83 0.38 0.78 0.28 0.22 
L2 Altered inclusion criteria            
L2.1      Wheeze past 12 months 1033 330 (32) 0.72 0.53 0.42 0.80 1.52 0.53 0.69 0.17 0.14 
L3 Altered scoring variables            
L3.1      Exclude trigger variables 1226 345 (28) 0.74 0.63 0.44 0.86 2.04 0.40 0.77 0.28 0.22 
L3.2      Exchange wheeze without  
     colds with current wheeze 
1226 345 (28) 0.82 0.53 0.40 0.88 1.73 0.34 0.77 0.28 0.21 
L4 Altered outcome definition            
L4.1      Severity: Wheeze past 12 months more than  
     4 episodes and use of asthma medication 
1030 86 (8) 0.86 0.61 0.17 0.98 2.19 0.23 0.84 0.32 -0.15* 
Sens, Spec, PPC, NPV, LR+, LR- are all presented for PARC score = 4. Abbreviations; R2: Nagelkerke’s, Sens: sensitivity, Spec: Specificity, PPV: positive predictive value, NPC: negative predictive value, LR-: Negative 
likelihood ratio, LR+: positive likelihood ratio. *The negative scaled Brier score is due to the large difference in the prevalence of the outcome in main analysis and the corresponding sensitivity analysis. 
 
Table 4 - Unmarked
 
*Score based on items described in table 3 for ALSPAC and LRC, respectively. Abbreviations; ALSPAC: Avon Longitudinal Study of Parents 
and Children, LRC: Leicestershire Respiratory Cohorts, IQR: Interquartile range 
 
Figure 1 - Unmarked
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Supplemental Text E3:  
Definition of the scaled Brier score and Nagelkerke’s R2 
In the following, let 𝑦𝑖  represent the outcome for child 𝑖 taking on the value 1 if the child has later 
asthma and 0 otherwise, and 𝑝𝑖  the predicted probability based on the baseline information of that 
child using the PARC tool. Let 𝑛 be the total number of children in the cohort and  ?̅? = 1𝑛 ∑ 𝑦𝑖𝑛𝑖=1  be 
the prevalence of the outcome.  
Scaled Brier score 
The Brier score evaluates the mean squared error of prediction1: 𝐵𝑟𝑖𝑒𝑟 = 1𝑛 ∑(𝑝𝑖 − 𝑦𝑖)2𝑛𝑖=1  
This score takes on the minimum value of 0 when 𝑝𝑖  predicts 𝑦𝑖  perfectly. To obtain a similar 
interpretation for this statistic as for R2 in linear regression models, we rescale this score as 𝐵𝑟𝑖𝑒𝑟𝑠𝑐𝑎𝑙𝑒𝑑 = 1 − 𝐵𝑟𝑖𝑒𝑟𝐵𝑟𝑖𝑒𝑟𝑚𝑎𝑥 
where 𝐵𝑟𝑖𝑒𝑟𝑚𝑎𝑥 is the Brier score evaluated with ?̅? replacing 𝑝𝑖  in the formula above. 𝐵𝑟𝑖𝑒𝑟𝑠𝑐𝑎𝑙𝑒𝑑 
takes on values between 0 and 1 with 1 representing perfect prediction and 0 a non-informative 
prediction model in which the outcome for each child is predicted with a constant equal to the 
prevalence ?̅?. 
Nagelkerke’s R2 
Nagelkerke’s R2 compares the likelihood of the prediction model with that of a non-informative 
model in which the outcome for each child is predicted with a constant equal to the prevalence ?̅?. It 
is calculated as follows1, 2:  
𝑅𝑁𝐾2 = 1 − (𝐿0 𝐿1⁄ )2 𝑛⁄1 − (𝐿0)2 𝑛⁄  
Where 𝐿1 and 𝐿0 are the likelihood of PARC and the non-informative models respectively. The 
denominator of this equation is simply used for rescaling and represents the maximum value that the 
numerator can attain (in a perfect model 𝐿1 = 1). As 𝐵𝑟𝑖𝑒𝑟𝑠𝑐𝑎𝑙𝑒𝑑, the statistic 𝑅𝑁𝐾2  thus takes on 
values between 0 and 1 with 1 representing perfect prediction and 0 the non-informative model. The 
likelihood function evaluated for the predictions of the PARC tool is given by: 𝐿1 = ∏ 𝑝1𝑦𝑖𝑛𝑖−1 (1 − 𝑝𝑖)(1−𝑦𝑖) 𝐿0 is calculated by replacing 𝑝𝑖  with ?̅? in this formula.  
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Table E2 (supplementary): Overview of the definitions of main analysis and sensitivity analyses in ALSPAC and LRC. 
 Analysis Definition changed Definition 
 ALSPAC   
A1 Main Analysis - Inclusion criteria: Wheeze or Cough in the past 12 months and saw a doctor for this. Scoring variables: 1)Sex 2)age 3)wheeze past 12 months 
4)number of wheeze attacks 5)number of days wheezed 6)breathless due to wheeze 7)exercise as trigger for wheeze 8)allergy as trigger for 
wheeze 9)rash in the joints 10)family history of asthma or bronchitis. Outcome definition: Wheeze past 12 months and use of asthma 
medication. 
A2 Altered inclusion criteria   
A2.1      Only children aged 1 year Inclusion criteria Age excluded as prediction variable 
A2.2      Only children aged 2 years Inclusion criteria Age excluded as prediction variable 
A2.3      Only children aged 3 years Inclusion criteria Age excluded as prediction variable 
A2.4      Wheeze past 12 months Inclusion criteria Past 12 months: Has he/she had periods when there was wheezing with whistling on his/her chest?  or Has he/she had wheeze?  
A2.5      Cough past 12 months Inclusion criteria Past 12 months: Has he/she ever had a time when he has coughed on and off for at least 2 days?  or Has he/she had cough?  
A3 Altered scoring variables   
A3.1      Exclude trigger variables Scoring variables Exclude item 7 and 8: Exercise and allergy as triggers for wheeze 
A4 Altered outcome definition   
A4.1      Severity: Wheeze past 12 months and use    
     of asthma medication at 3 or more episodes 
Outcome Has he had wheeze in the past 12 months?  AND Please indicate which of the following have been given to your child in the past 12 months 
(answer category: asthma medication, on 3 or more episodes) 
    
 LRC   
L1 Main analysis - Inclusion criteria: Wheeze or cough apart from colds in the past 12 months and saw a doctor for wheeze or cough. Scoring variables: 1)Sex 
2)age 3)wheeze apart from colds 4)number of wheeze attacks 5)wheeze interference with daily life 6)shortness of breath due to wheeze 
7)exercise or emotion as trigger for wheeze 8)allergy as trigger for wheeze 9)child ever had eczema 10)family history of wheeze, asthma or 
bronchitis. Outcome: wheezing or whistling in the chest in the last 12 months AND use of asthma medication 
L2 Altered inclusion criteria   
L2.1      Wheeze past 12 months Inclusion criteria Has your child has wheezing or whistling in the chest in the last 12 months? 
L3 Altered scoring variables   
L3.1      Exclude trigger variables Scoring variables Exclude item 7 and 8: Exercise and allergy as triggers for wheeze 
L3.2      Exchange wheeze without  
     colds with current wheeze 
Scoring variables Exchange item 3 ‘wheeze without colds’ with ‘wheezing or whistling in the chest in the last 12 months’ 
L4 Altered outcome    
L4.1      Severity: Wheeze past 12 months more than  
     4 episodes and use of asthma medication 
Outcome More than 4 episodes of wheeze past 12 months and use of asthma medication past 12 months 
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Supplementary table E3: Comparison of four asthma prediction tools for preschool children 
 
 PARC API* Isle of Wight PIAMA 
No. (included in analysis) 1226 776 336 2054 
Inclusion criteria     
   Age (y) 1-3 2-3 4 1-4 
   Symptoms Health care visit 
because of respiratory 
problems plus ≥1 of the 
following: wheeze, 
cough without colds, 
cough at night 
Entire cohort 
(including a majority 
of children without 
symptoms) 
Wheeze at ages 1,2 
and 4 y 
Wheeze or cough at 
night without colds 
in the past 12 
months 
Outcome definition     
   Age (y) 6-8 8 10 7-8 
   Prediction interval (y) 5 5 6 3-7 
   Criteria Wheeze plus asthma 
medication (past 12 
months) 
Doctor’s diagnosis of 
asthma plus current 
wheeze or >3 
episodes of wheeze 
(past 3 months) 
Current wheeze At ages 7 and 8 y: 
current wheeze or 
prescription of 
inhaled 
corticosteroids or doctor’s diagnosis of 
asthma (past 12 
months) 
Outcome prevalence 28% 14% 37% 12% 
Predictor variables 
included in tool 
Male sex, age, wheeze 
without colds, frequent 
wheeze, activity 
disturbance, shortness 
of breath, exercise-
related wheeze/cough, 
aeroallergen-related 
wheeze/cough, eczema, 
parental asthma or 
bronchitis 
Wheeze, frequent 
wheeze, wheeze 
without colds, 
eczema, parental 
asthma, blood 
eosinophilia, allergic 
rhinitis 
Family history of 
asthma, recurrent 
chest infections (at 2 
y), skin prick test 
positive (at 4 y), 
nasal symptoms (at 1 
y) 
Male sex, post term 
delivery, 
wheeze/dyspnea 
without colds, 
frequent wheeze, 
eczema, respiratory 
infections, inhalation 
medication 
(parents), parental 
education 
Method used to derive tool Penalized logistic 
regression 
Combination of 
predictors was 
chosen that yielded 
the highest PPV and 
specificity 
Stepwise backward 
logistic regression 
Stepwise backward 
logistic regression 
Performance measures Score cutoff ≥5 Loose API Score cutoff ≥3 Score cutoff ≥20 
   Youden index 0.43 0.32 0.38 0.36 
   Sensitivity (%) 72 51 53 60 
   Specificity (%) 71 81 85 76 
   PPV (%) 49 29 68 23 
   NPV (%) 86 91 74 94 
   +LR 2.48 7.43 3.41 2.50 
   -LR 0.39 0.75 0.56 0.53 
PARC: Predicting Asthma Risk in Children (19), API: Asthma Predictive Index (10), Isle of Wight risk score (13), PIAMA risk score (18), Youden 
Index: Reported for cutoff where the sum of sensitivity and specificity was maximal. It is possible that a higher sum of sensitivity and 
specificity exists at a cutoff point that was not reported in the respective studies. PPV: positive predictive value, NPV: negative predictive 
value, +LR: positive likelihood ratio, -LR: negative likelihood ratio 
*To have a prediction interval comparable with the one in our tool, we focused here on the API for prediction at 8 years. 
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